Should I Buy NEUP? NEUP 2026 Analysis

Should You Buy Neuphoria Therapeutics Inc (NEUP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.020

1 Day change

0.25%

52 Week Range

21.400

Analysis Updated At

2026/01/26

Neuphoria Therapeutics Inc (NEUP) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financials are weak, with no revenue growth and significant losses. Additionally, the recent failure in Phase 3 trials for social anxiety disorder increases the risk profile of the stock. While there is some value in the positive Phase 2b PTSD data, the lack of strong technical or proprietary trading signals, coupled with neutral trading sentiment and no recent news catalysts, suggests holding off on investment until clearer positive signals emerge.

Technical Analysis

The MACD is slightly positive at 0.0651, indicating mild bullish momentum, but it is contracting. RSI is at 66.656, which is neutral and does not indicate overbought or oversold conditions. Moving averages are converging, showing no clear trend. The price is trading near the pivot level of 4.131, with resistance at 4.25 and support at 4.013. Overall, the technical indicators suggest a neutral trend with no strong buy signal.

Options Data

Positive Catalysts

Positive Phase 2b PTSD data provides some value to the company.

Neutral/Negative Catalysts

Failure in Phase 3 trials for social anxiety disorder has significantly increased the company's risk profile. Analyst price target was lowered from $21 to $7, reflecting diminished confidence in the stock.

Financial Performance

In Q1 2026, the company reported no revenue growth (0% YoY), a net loss of -$9,906,504 (up 1130.95% YoY), and an EPS of -4.41 (0% YoY). Gross margin remains at 0%. The financials indicate poor performance with no signs of improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright maintains a Buy rating but significantly lowered the price target from $21 to $7. The analyst notes increased risk due to the Phase 3 trial failure, though the positive Phase 2b PTSD data provides some value.

3 Analyst Rating

Wall Street analysts forecast NEUP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEUP is 9.77 USD with a low forecast of 2.3 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 4.010

Low

2.3

Averages

9.77

High

Current: 4.010

Low

2.3

Averages

9.77

High

H.C. Wainwright

Buy

downgrade

$21 -> $7

AI Analysis

2025-12-05

Reason

H.C. Wainwright

Price Target

$21 -> $7

AI Analysis

2025-12-05

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Neuphoria Therapeutics to $7 from $21 and keeps a Buy rating on the shares. The firm says the company is "caught between a rock and a hard place right now." With the Phase 3 social anxiety disorder failure, Neuphoria's risk profile "has increased significantly," the anlayst tells investors in a research note. However, the firm says the positive Phase 2b post-traumatic stress disorder data still provides value to the company.

Lucid Capital

Elemer Piros

Buy -> Neutral

downgrade

$81

2025-10-21

Reason

Lucid Capital

Elemer Piros

Price Target

$81

2025-10-21

downgrade

Buy -> Neutral

Reason

Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEUP

Unlock Now

NEUP Should I Buy

NEUP Should I Buy

Should You Buy Neuphoria Therapeutics Inc (NEUP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch